Table 5.
HR estimates of progression-free survival between statins and lung cancer
No. of reports | Pooled HR (95% CI) | I2 (%) | P for heterogeneity | |
---|---|---|---|---|
Overall estimation | 6 | 0.93 (0.76–1.13) | 39.90 | 0.14 |
Subgroup analysis | ||||
Study design | ||||
Cohort | 3 | 0.74 (0.47–1.17) | 58.50 | 0.29 |
RCT | 3 | 0.99 (0.87–1.13) | 0 | 0.37 |
Cancer type | ||||
NSCLC | 5 | 0.88 (0.65–1.19) | 50.10 | 0.093 |
SCLC | 1 | 0.98 (0.85–1.13) | ||
Combined treatment | ||||
TKIs | 3 | 0.85 (0.49–1.49) | 70.90 | 0.032 |
Chemotherapy | 2 | 0.99 (0.86–1.12) | 0.00 | 0.836 |
Abbreviations: NSCLC, non-small-cell lung cancer; RCT, randomized controlled trial; SCLC, small cell lung cancer; TKIs, tyrosine kinase inhibitors.